Study Details

General Information

Abbott Schizophrenia 855

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers

ProtocolM10-855
IdentifierSite Number 26 PO Number 4200013024
UIDcc2f3eea-5974-42c4-bf9e-615a7e1907af
StatusDone - Archived
Phase2
CategorySchizophrenia / Adult
Launch Year2012
NCT Number-
Created2012-05-18 14:00
Last Updated2012-05-18 14:00

Description

Key Elements: Phase 2 Study of the safety and efficacy of ABT-126(IP) in the treatment of Cognitive Deficits in Schizophrenia in non-smokers. • $75 per visit. • 8 month long trial. • 17 office visits every 2 weeks. • 1 in 4 chance of receiving placebo (25mg, 50mg, 75mg, and placebo). • Medication is taken 3 capsules every day for 24 weeks. • Most common side effects: Headaches.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment Closed2013-06-17No
Enrollment Open2012-07-19No
First Patient First VisitNo
Site Initiation Mtg.2012-05-10No
PI Meeting Start2012-05-10No
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2014-09-22No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMartinez, GilbertGJMartinezNo
RecruiterAguirre, SandraSAguirreNo
CoordinatorBarnett, OmarOBarnettNo
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorAbbVie
DivisionAbbVie
TeamAbbott
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB RefIRB ID No. 27068/9
CRO
CRO RefCRA: Saritza Stevens Tel 310-948-9970
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?